
TWiV 606: Evidence-based science and medicine for COVID-19
About this episode
Daniel Griffin provides his weekly update on the COVID-19 clinical situation, followed by our discussion of tests of an inactivated vaccine, results of serological surveys, an inhibitor of the cell protease needed for virus entry, and answers to listener questions.
Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler
Guest: Daniel Griffin
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Inactivated SARS-CoV-2 vaccine protects monkeys (bioRxiv)
- Saliva is more sensitve than nasopharyngeal swab (medRxiv)
- NY serological survey results (NY Times)
- FDA caveats on serological tests (FDA)
- Federal guidelines on when to open
- When to open: Roadmap, blog, video explainer
- Blocking TMPRSS2 blocks SARS-CoV-2 infection (Cell)
- Lawmakers want human challenge studies (Science)
- Letters read on TWiV 606
- Image credit
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees.
Send your virology questions and comments to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology

TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology

TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology

TWiV 1307: My heart breaks for flu
This Week in Virology

TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology